Pfizer (NYSE:PFE) Trading Down 1% - Time to Sell?

Key Points

• Pfizer shares fell 1% to about $28, near the analyst consensus price target of $28.28. Analysts broadly maintain a “Hold” view, with several recently lowering their price targets.
• The company reported stronger-than-expected quarterly results, with $0.77 in adjusted EPS versus $0.68 expected and revenue of $15.03 billion. Positive pipeline developments include regulatory review of its Lyme disease vaccine candidate and encouraging real-world data for Vyndamax.
• Dividend sustainability remains a key risk: Pfizer offers a roughly 6.1% yield, but its payout ratio is above 200%, while patent expirations, declining legacy-product volumes, debt and reliance on cost cuts continue to weigh on the turnaround outlook.

Pfizer Inc. (NYSE:PFE - Get Free Report) traded down 1% during trading on Thursday . The company traded as low as $27.83 and last traded at $28.0050. Approximately 29,931,103 shares were traded during trading, a decline of 28% from the average daily volume of 41,855,605 shares. The stock had previously closed at $28.30.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer provided an update from its Korean post-marketing study of Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM). Additional real-world evidence could support the drug’s commercial durability and strengthen confidence in Pfizer’s rare-disease portfolio. Pfizer’s Korean Vyndamax Study Update
• Positive Sentiment: Pfizer has begun the European Medicines Agency review of its Lyme disease vaccine candidate. Regulatory review is an important step toward potentially expanding the company’s future vaccine revenue base, although approval and commercialization remain uncertain. Pfizer Starts EMA Review for Its Lyme Disease Vaccine
• Positive Sentiment: Commentary on Pfizer’s pipeline and oncology portfolio argues that valuation and diversification may offer turnaround potential if newer medicines offset declining legacy products. Pfizer’s latest quarterly results also exceeded consensus estimates, with revenue growth and earnings of $0.77 per share versus expectations of $0.68.
• Neutral Sentiment: Pfizer remains a prominent high-yield dividend stock, but comparisons with Abbott emphasize the trade-off: Pfizer offers income and potential recovery upside, while Abbott has steadier diversification and dividend-growth characteristics. Pfizer vs. Abbott Dividend Comparison
• Negative Sentiment: Investors are increasingly focused on Pfizer’s dividend sustainability rather than its headline payout ratio, which is above 100%. The key risks are free-cash-flow generation, debt and whether cost reductions can support the payout while the company rebuilds growth. The Most Concerning Thing About Pfizer’s Dividend
• Negative Sentiment: Critics say Pfizer’s turnaround case relies heavily on cost savings and targets that do not imply meaningful growth until later in the decade. Patent expirations and declining volumes could therefore remain overhangs, helping explain why brokerages maintain a consensus “Hold” rating. Can Cost Cuts and 2030 Targets Save Pfizer Stock?

Analysts Set New Price Targets

PFE has been the subject of a number of research analyst reports. Cantor Fitzgerald restated a "neutral" rating and issued a $27.00 target price on shares of Pfizer in a research report on Monday, July 6th. BMO Capital Markets lowered their price target on Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, July 13th. Guggenheim cut their price objective on Pfizer from $35.00 to $31.00 and set a "buy" rating for the company in a report on Friday, August 7th. Weiss Ratings cut Pfizer from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, August 17th. Finally, HSBC lowered Pfizer from a "buy" rating to a "hold" rating and lowered their target price for the stock from $32.00 to $28.00 in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $28.28.

Pfizer Stock Performance

The stock has a market cap of $159.62 billion, a price-to-earnings ratio of 36.85 and a beta of 0.34. The company's 50-day simple moving average is $25.44 and its 200-day simple moving average is $26.29. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company's quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. Pfizer's dividend payout ratio (DPR) is currently 226.32%.

Institutional Trading of Pfizer

A number of hedge funds have recently bought and sold shares of PFE. Godfrey Financial Associates Inc. purchased a new stake in shares of Pfizer in the 4th quarter valued at approximately $26,000. Keb Asset Management LLC purchased a new position in Pfizer during the 2nd quarter worth approximately $26,000. Field & Main Bank purchased a new position in Pfizer during the 2nd quarter worth approximately $27,000. HFM Investment Advisors LLC raised its stake in Pfizer by 61.0% during the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 427 shares during the period. Finally, Evolution Wealth Management Inc. lifted its holdings in shares of Pfizer by 132.2% in the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source